OncoHealth

Gain exclusive insights from Dr. Laura Bobolts, PharmD, BCOP, Senior Vice President of Clinical Strategy and Growth at OncoHealth as she summarizes pivotal #ASCO24 presentations on key clinical trials that could reshape treatment approaches for patients with breast cancer, lung cancer, and melanoma. Don't miss out - register here! https://lnkd.in/gX9hXh46

We’ve got you covered with all the essentials for your night out in Vegas. Come pick up your Preparedness Kit in Booth #1637 - you’ll thank us later!

3️⃣ More studies that caught my 👀 as #ASCO2024 comes to an end… —1️⃣— Plenary session found palliative care delivered via telehealth was as effective as in-person care in maintaining quality of life! 🔹 Quality of life at 24 weeks in advanced lung cancer patients scored 99.67 for digital care vs 97.67 for in-person care, via the FACT-L score 🔹 👉 “If there is one message for practices after getting back from the ASCO meeting, it is to reflect on when and how they are currently delivering ✨virtual care✨and what the opportunities for improvement may be.”👈 Dr. Monika K Krzyzanowska via ASCO Daily News —2️⃣— IMROZ: Isatuximab + VRd (bortezomib, lenalidomide, dex) reduces the risk of progression or death by 40% over VRd in newly diagnosed transplant INeligible multiple myeloma. 🔹 Isatuximab (Sarclisa) + VRd expected to get FDA approved by Sept 27th BUT the trial is published now, full text in the New England Journal of Medicine, supporting off-label insurance coverage for many per CMS —3️⃣— ASC4FIRST: Asciminib demonstrated ✨superiority in newly diagnosed CML (chronic myeloid leukemia)✨over standard of care TKI (imatinib, dasatinib, nilotinib, bosutinib) with improved major molecular response rates at week 48 (67.7% vs 49.0%) with less toxicity. 🔹 Asciminib (Scemblix) received Breakthrough Therapy designation for 1st line use May 2024, priority review status likely to follow 🔹 This trial is published in full text in the New England Journal of Medicine now, supporting off-label insurance coverage for many per CMS ❓Wonder what my top top tippity top favorite studies were from #ASCO❓Stay tuned for more!! - Laura Bobolts, PharmD, BCOP What was your✨top✨favorite #ASCO study❓ #ASCO #Cancer #DigitalHealth #Scemblix #Sarclisa #OncoHealth

Ready for more #ASCO2024 data, hot off the press like hot cakes 🥞(can you tell I’m hungry?) Laura Bobolts, PharmD, BCOP here reporting from the biggest cancer conference in the world! PALMARES-2, an Italian study evaluating the real world efficacy of CDK4/6 inhibitors + endocrine tx in HR+/HER2- metastatic breast cancer (MBC) 👉 Abemaciclib (Verzenio) or Ribociclib (Kisqali) use improved progression-free survival vs Palbociclib (Ibrance) but no significant difference btw Abema compared to Ribo. Many payers prefer Abemaciclib or Ribociclib over Palbociclib today… but they need to be ready for Inavolisib to shake things up! Inavolisib is likely to get FDA approval before Nov 27th in combo w/ ✨Palbociclib✨& Fulvestrant in PIK3CA-mutated, HR+/HER2- MBC w/ recurrence after adjuvant endocrine tx 👉57%⬇️🎉 in the risk of progression or death. Since Inavolisib was only studied w/ Palbo & not Ribo or Abema, payers may need to revisit their strategies in this PIK3CAm population. #ASCO #breastcancer #CDK46inhibitors #Ibrance #Kisqali #Verznio

It’s getting wild at #ASCO - 3 people standing ovation in the middle of the ADRIATIC trial! Durvalumab (Infinzi) consolidation is a 🎉new standard of care🎉 in limited stage SMALL cell lung cancer (SCLC) following chemoradiotherapy, adding✨22.5 months✨of life to patients in this cancer well known to rapidly progress to an incurable stage. Key points: ✨Median overall survival: 55.9 months with durvalumab vs 33.4 mo with placebo (HR=0.73) ✨ADRIATIC is the 1st positive phase 3 immunotherapy trial in limited stage SCLC!!! ✨Durvalumab consolidation is given for a MAX of 2 years in limited stage SCLC ✨ADRIATIC trial is not published in full-text yet (keep your eye out!), not in NCCN yet either - given this, CMS doesn’t broadly support off-label coverage. This could be case by case. Data changes too fast in oncology! What do you think about this one? 1st targeted therapy for limited stage SCLC! #ASCO #ADRIATIC #Imfinzi #lungcancer #oncohealth

We have a ✨Semi-Standing Ovation✨ at #ASCO2024 & guess what the clinical trial name was 🤔 —> LAURA Yes 👋Laura Bobolts, PharmD, BCOP here reporting on the LAURA trial! I can’t make this stuff up people! Happy to take the applause! 😝 Ok, time to get serious (totally not me, but here we go)… LAURA trial defines consolidation Osimertinib (Tagrisso) as the 🎉new “immediate” standard of care🎉 after chemoradiotherapy for stage III unresectable EGFR mutated non-small cell lung cancer (NSCLC) with ✨almost a 3-year✨ benefit (PFS 39.1 months osimertinib vs 5.6 months placebo, HR=0.16) Key points: ✨Osimertinib is indicated in early stage & metastatic EGFR+ NSCLC, this trial fills the gap supporting use after chemorads in stage III unresectable NSCLC ✨Osimertinib use after chemorads is indefinite (until progression or death), unlike early stage & unlike 1 yr durvalumab consolidation ✨81% on placebo crossed over & received Osimertinib later, strengthening these results ✨EGFR mutation testing is CRITICAL and MUST be done in NSCLC ✨Off-label Osimertinib insurance coverage is likely supported for many TODAY according to the full-text publication of LAURA How excited are you about these results? I rarely hear things stated as a new ✨immediate✨ standard of care!! Get ready everyone! #ASCO #Tagrisso #lungcancer #NSCLC #oncohealth

#ASCO2024 Plenary 2️⃣ 👉 NADINA trial defines neoajuvant (pre-op) immunotherapy as a 🎉new standard of care🎉 over adjuvant (post-op) in macroscopic resectable stage III melanoma 68% reduction in risk of recurrence, progression or death with using neoadj nivolumab + ipilimumab (+/- additional therapy) vs pure adjuvant nivolumab 👋 Laura Bobolts, PharmD, BCOP here👋 & I have to be honest, this clinical trial design makes my head spin 🤔 … Resectable stage III melanoma patients were randomized to either: 1️⃣ 2 cycles neoadj Nivo 240 mg + Ipi 80 mg then surgery (lymph node dissection) ✨AND✨ if major pathological response (MPR)👉 no more therapy; if no MPR 👉 ~ 11 months adjuvant Nivo alone (BRAF-) or Dabrafenib/Trametinib (BRAF+) —OR— 2️⃣ surgery then 1 year adjuvant nivolumab All +/- adjuvant radiation Is your head spinning yet? It isn’t peri-operative Nivo+Ipi, only 2 cycles pre-op then maybe nivolumab alone later, maybe not. Good news: ~60% patients needed only 2 cycles of Nivo/Ipi and that was it! Complex, yes 🤔 Are payers going to know how to look for a major pathological response to determine if further therapy is needed? Are payers going to cover 6 or 12 months of Nivo/ipi when only 2 cycles (6 weeks) are needed here? NADINA trial was just published in the New England Journal of Medicine which tells you it is kinda a big deal🚨 #ASCO #Melanoma #Opdivo #Yervoy

#ASCO2024 Plenary session is underway! Get ready for some great data! 🤗 ESOPEC trial 👉 improved overall survival with perioperative FLOT (5-FU, leucovorin, oxaliplatin, docetaxel) vs neoadjuvant CROSS (carboplatin, paclitaxel, radiation) in resectable esophageal adenocarcinoma 👉 66 months vs 37 months (HR=0.70) But will this change standard of care for good? 🔵Immunotherapy was not studied & today Nivolumab is indicated after the CROSS regimen in those without a pahological complete response. 🔵FLOT will likely be adopted more in fit patients, but CROSS (+/-) adjuvant nivolumab is still a viable option, especially for elderly or less fit patients with comorbidities #ASCO #esophagealcancer #ESOPEC #oncohealth

“Today we learned that again we have to change the way we think of HER2 testing” - Ian Krop, MD, PhD DESTINY-Breast06 👉 An efficacy signal (although not statistically powered) was seen with trastuzumab deruxtecan (T-DXd; Enhertu) in ✨HER2-UltraLow (IHC 0 w/ any HER2 staining)✨ HR+ endocrine pretreated metastatic breast cancer (PFS 13.2 months T-DXd vs 8.3 months chemo, HR=0.78) Fantastic discussant, let me stew over this data, more to come! Laura Bobolts, PharmD, BCOP reporting for OncoHealth from #ASCO. Today is the busiest day so get ready!!! #ASCO2024 #Enhertu #HER2ultralow #breastcancer #oncohealth

👋 Laura Bobolts, PharmD, BCOP here reporting from #ASCO2024 Will we ever answer the age old question 👉should we use a CDK4/6 inhibitor after disease progression on a CDK4/6i in HR+/HER2- metastatic breast cancer❓ PostMONARCH trial just resulted 👉 27% ⬇️ in risk of disease progression or death with adding the CDK4/6i Abemaciclib to Fulvestrant after disease progression on a CDK4/6i Let’s dive into the data more: 🔵Absolute ✨investigator-assessed✨ PFS (progression-free survival) benefit with adding Abemaciclib to Fulvestrant vs Fulvestrant alone was only ✨0.7 months✨(yes, significant w/o even adding 1 month of benefit; 6.0 months Abema/Fulv vs 5.3 mo Fulv) 🔵PFS benefit most seen with adding Abemaciclib after progression on a CDK4/6i if: 1️⃣ >/= 12 month duration of last CDK4/6i 2️⃣ no visceral mets (most bone only disease) 3️⃣ switching to a different CDK4/6i & switching the endocrine backbone (ex: Abemaciclib/Fulvestrant after progression on Palbociclib/AI) 🔵Results are similar to the MAINTAIN trial 👉 2.5 month absolute PFS benefit with Ribociclib/Fulvestrant after progression on mainly Palbociclib/AI. Do you think postMONARCH will change practice & we’ll see more prescribing of a 2nd trial of a CDK4/6i? Call me cautious but … we didn’t see a huge change in practice after the MAINTAIN trial & FYI, the monthly cost of Abemaciclib (Verzenio) is listed at $15,406! Follow this page for more #ASCO2024 updates! #ASCO #breastcancer #postMONARCH #Verzenio #OncoHealth